Business Context and Reporting Period
Company: NeOnc Technologies Holdings, Inc. (NTHI)
Filing Type: Form 8-K (Current Report)
Date of Report: June 16, 2026
Reporting Period: Single event date (June 16, 2026)
Business Context: The Company is an emerging growth company developing therapies for aggressive brain tumors. This filing serves as a Regulation FD disclosure regarding a regulatory milestone for its lead candidate, NEO212.
Key Financial Metrics
This Form 8-K is a current report regarding a specific corporate event and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity metrics.
Material Changes
The primary material change reported is a regulatory advancement:
- Regulatory Approval: The Department of Health – Abu Dhabi (DOH) granted Investigational New Drug (IND) status for NEO212.
- Product Details: NEO212 is an orally administered perillyl alcohol-temozolomide carbamate conjugate.
- Indication: The drug is being developed for patients with aggressive brain tumors.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release (Exhibit 99.1) announcing the IND status but does not include forward-looking guidance, financial outlook, or specific management commentary within the body of this 8-K text.
Risks and Contingencies: The filing explicitly states that the information provided is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section, nor is it incorporated by reference into other filings except as expressly set forth. No specific risks or contingencies are detailed in this document.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for details on the scope of the IND approval and next clinical trial steps.
- Confirm the specific jurisdictional limitations of the Abu Dhabi DOH approval versus other global regulatory bodies.
- Review the Company's most recent 10-K or 10-Q filings for current cash runway and burn rate, as this 8-K contains no financial data.
- Monitor subsequent filings for the initiation of clinical trials in Abu Dhabi or expansion to other regions.